Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: a Review of the Evidence

World Allergy Organization Journal

Michael Blaiss¹  G Walter Canonica² 

[1] Division of Clinical Immunology and Allergy, University of Tennessee Health Science Center, Memphis, TN;Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, Genoa, Italy

关键词: urticaria;    second-generation antihistamines;    desloratadine;    anti-inflammatory;    antihistamine;    allergic rhinitis;   

Others  :  1145620
DOI  :  10.1097/WOX.0b013e3182093e19

【 摘 要 】

The allergy cascade presents widespread inflammatory and proinflammatory activation, robust cytokine and chemokine signaling, and heterogeneous immune and endothelial responses that lead ultimately to the manifestations of allergic reaction. Histamine, a small peptide with inherent vasoactive properties, is released from granules contained within mast cells, basophils, lymphocytes, and other reservoirs and interacts with histamine receptors to regulate numerous cellular functions involved in allergic inflammation and immune modulation. Of the known histamine receptors, the H₁-receptor is most clearly associated with potentiation of proinflammatory immune cell activity and enhanced effector function and is the prime focus of suppressive therapy. Second-generation oral H₁-antihistamines, such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine, are mainstays of allergy treatment, acting as highly specific, long-acting H₁-receptor agonists at its unique receptor. The ongoing identification of immune effector cells and mediators involved in the allergic cascade indicates that further research is necessary to define the role of antihistamines such as desloratadine in anti-inflammatory therapy.

【 授权许可】

   
2011 World Allergy Organization; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Akdis CA, Simons FER: Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006, 533:69-76.
• [2]Akdis CA, Jutel M, Akdis M: Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy 2008, 94:67-82.
• [3]Schneider E, Rolli-Derkinderen M, Arock M, Dy M: Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 2002, 23:255-263.
• [4]Baena-Cagnani CE: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001, 56:21-27.
• [5]Zuberbier T, Asero R, Bindslev-Jensen C: EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009, 64:1418-1426.
• [6]Thurmond RL, Gelfand EW, Dunford PJ: The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53.
• [7]Das AK, Yoshimura S, Mishima R, Fujimoto K, Mizuguchi H, et al.: Stimulation of histamine H1 receptor up-regulates histamine H1 receptor itself through activation of receptor gene transcription. J Pharmacol Sci 2007, 103:374-382.
• [8]Simons FER: Advances in H1-antihistamines. N Engl J Med 2004, 351:2203-2217.
• [9]Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al.: Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and Aller-Gen). Allergy 2008, 63(Suppl 86):8-160.
• [10]Zuberbier T, Asero R, Bindslev-Jensen C: EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1427-1443.
• [11]del Cuvillo A, Mullol J, Bartra J, Dávila I, Jáuregui I, et al.: Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006, 16(Suppl 1):3-12.
• [12]Scadding G: Predicting and establishing the clinical efficacy of a histamine H1- receptor antagonist: desloratadine, the model paradigm. Clin Drug Invest 2005, 25:153-164.
• [13]Simons FE: Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002, 113(Suppl 9A):38S-46S.
• [14]Lippert U, Möller A, Welker P, Artuc M, Henz BM: Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1-and H2-receptor antagonists. Exp Dermatol 2000, 9:118-124.
• [15]Leurs R, Church MK, Taglialatela M: H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002, 32:489-498.
• [16]Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, et al.: ACCEPT-1 Study Group. Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy 2009, 64:1516-1523.
• [17]Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009, 123:672-679.
• [18]Zuberbier T, Canonica GW: Desloratadine significantly decreases total symptoms scores in subjects with persistent allergic rhinitis: ACCEPT-2 study in collaboration with GA2LEN. Ann Allergy Asthma Immunol 2009, 102:A119.
• [19]Canonica GW, Tarantini F, Compalati E, Penagos M: Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007, 62:359-366.
• [20]Ortonne J-P, Grob J-J, Auquier P, Dreyfus I: Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007, 8:37-42.
• [21]Pradalier A, Neukirch C, Dreyfus I, Devillier P: Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007, 62:1331-1334.
• [22]Berger WE, Lumry WR, Meltzer EO, Pearlman DS: Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006, 27:214-223.
• [23]Kim K, Sussman G, Hébert J, Lumry William, Lutsky B, Gates D: Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2006, 96:460-465.
• [24]Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG: Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006, 96:363-368.
• [25]Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D: Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomised, placebo-controlled trial. J Am Acad Dermatol 2003, 48:535-541.
• [26]Simons FER, Prenner BM, Finn A Jr: Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003, 111:617-622.
• [27]Ring J, Hein R, Gauger A, Bronsky E, Miller B: Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Int J Dermatol 2001, 40:72-76.
• [28]Aerius Summary of Product Characteristics Brussels, Belgium: SP Europe; 2007.
• [29]Clarinex® (desloratadine) product information Kenilworth, NJ: Schering-Plough; 2007.
• [30]Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R: Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001, 60:1133-1142.
• [31]Greasley PJ, Clapham JC: Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur J Pharmacol 2006, 553:1-9.
• [32]National Center for Biomedical Information. [Entrez Gene Website.] NFKB1: nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [[Homo sapiens]] Available at: http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4790&ordinalpos=6&itool=EntrezSystem2.PEntrez.Gene.Gene_ResultsPanel.Gene_RVDocSum webcite. Accessed July 11, 2010
• [33]Costa T, Cotecchia S: Historical review: negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol Sci 2005, 26:618-624.
• [34]de Ligt RA, Kourounakis AP, IJzerman AP: Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 2000, 130:1-12.
• [35]Bakker RA, Wieland K, Timmerman H, Leurs R: Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur J Pharmacol 2000, 387:R5-R7.
• [36]Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, et al.: Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol 2002, 449:229-237.
• [37]Wu R-L, Anthes JC, Kreutner W, Harris AG, West RE Jr: Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-κB activity consistent with inverse agonism at the histamine H1 receptor. Int Arch Allergy Immunol 2004, 135:313-318.
• [38]Rothenberg ME, Hogan SP: The eosinophil. Annu Rev Immunol 2006, 24:147-174.
• [39]Borish LC, Steinke JW: 2. Cytokines and chemokines. J Allergy Clin Immunol 2003, 111(Suppl):S460-S475.
• [40]Lebel B, Bousquet J, Czarlewski W, Campbell AM: Loratadine (L) reduces RANTES release by an epithelial cell line. J Allergy Clin Immunol 1997, 99:S444. Abstract 1802
• [41]Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L: Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy 2005, 60:80-85.
• [42]Di Sciascio MB, Vianale G, Verna N, Petrarca C, Perrone A, et al.: Eosinophil recruiting chemokines are down-regulated in peripheral blood mononuclear cells of allergic patients treated with deflazacort or desloratadine. Int J Immunopathol Pharmacol 2007, 20:745-751.
• [43]Cyr MM, Hayes LM, Crawford L, Baatjes AJ, Keith PK, Denburg JA: The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int Arch Allergy Immunol 2005, 138:209-216.
• [44]Mullol J, Roca-Ferrer J, Alobid I, Pujols L, Valero A, et al.: Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy 2006, 36:52-58.
• [45]Wang YH, Taché Y, Harris AG, Kreutner W, Daly AF, Wei JY: Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 2005, 60:117-124.
• [46]Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcεRI cells. Clin Exp Allergy 1997, 27:559-567.
• [47]Lippert U, Krüger-Krasagakes S, Möller A, Kiessling U, Czarnetzki BM: Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995, 4(part 2):272-276.
• [48]Weller K, Maurer M: Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol 2009, 129:2723-2726.
• [49]Tworek D, Bochenska-Marciniak M, Kupczyk M, Górski P, Kuna P: The effect of 4 weeks treatment with desloratadine (5 mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. Pulm Pharmacol Ther 2006, 20:244-249.
• [50]Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W: Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001, 31:1369-1377.
• [51]Zhao Y, Leung PC, Woo KS, Chen GG, Wong YO, Liu SX, van Hasselt CA: Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1). Inflamm Res 2004, 53:664-669.
• [52]Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel A-B: Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997, 27:1167-1174.
• [53]Vignola AM, Crampette L, Mondain M, Sauvère G, Czarlewski W, Bousquet J, Campbell AM: Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995, 50:200-203.
• [54]Traidl-Hoffmann C, Münster I, Ring J, Behrendt H: Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol 2006, 140:315-320.
• [55]DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol 2007, 8:271-283.
• [56]DuBuske LM: Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother 2005, 6:2511-2523.
• [57]Agrawal DK: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs 2001, 10:547-560.
• [58]Ciprandi G, Cirillo I: Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: a pilot study. J Biol Regul Homeost Agents 2010, 24:177-183.
• [59]Ciprandi G, Cirillo I, Mora F, La Rosa M: Ebastine improves nasal symptoms and airflow and affects response to decongestion test in patients with persistent allergic rhinitis: a pilot study. Allergy Asthma Proc 2007, 28:578-581.
• [60]Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, et al.: Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005, 5:1800-1808.
• [61]Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA: Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Eur Ann Allergy Clin Immunol 2005, 37:25-29.
• [62]Gillard M, Strolin Benedetti M, Chatelain P, Baltes E: Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005, 54:367-369.